A Study of IBI363 in Subjects With Advanced Melanoma

This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients

Trial Details

NCT ID
NCT06081920
Phase
PHASE2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • IBI363
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Histologically and/or cytologically confirmed, unresectable, locally advanced or metastatic melanoma (according to the American Joint Committee on …
  • At least one measurable lesion (target lesion) per RECIST v1.1.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  • Life expectancy of 3 months or more.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →